Search

Displaying results 891 - 900 of 7639 in total
  1. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113]

  2. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Fat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041 … It is a rich source of monounsaturated and saturated fatty acids [A33040] that mainly contains approximately 33% [DB04224], 25% [DB03796], and 33% [DB03193] [A20409] but does not contain caffeine or theobromine

    Mixtures: Up and Up Hemorrhoidal
  3. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other

  4. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. … Cangrelor was approved by the FDA in June 2015 for intravenous application.

  5. Drug

    Zinc gluconate

    go.drugbank.com/drugs/DB11248
    ApprovedInvestigationalVet approved

    Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA [L2081]. … to 12 weeks [L422].

    Mixtures: Super Daily No 2, Zinc and Algin Tab Nu Life
  6. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy.

  7. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    [L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411] … DNA polymerase-based therapies, and their use is often limited by toxicities like myelosuppression and renal injury.

  8. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.

    Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride
  9. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [L32813] Vildagliptin is currently under investigation in the US. … [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote

  10. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A174154] By comparison, the angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of

    Mixtures: VALSARTAN HCT MK 80 MG/12.5 MG COMPRIMIDOS RECUBIERTOS, VARTERAL NF® 320 MG / 5 MGCategories: Agents Acting on the Renin-Angiotensin System